Satralizumab Disease Interactions
There are 3 disease interactions with satralizumab.
Satralizumab (applies to satralizumab) active hepatitis B
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis
Satralizumab is contraindicated in patients with active hepatitis B infection. All patients should be screened for hepatitis B before treatment initiation.
Satralizumab (applies to satralizumab) tuberculosis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent
Satralizumab is contraindicated in patients with active or untreated latent tuberculosis. All patients should be screened for tuberculosis before treatment initiation and monitored for the development of symptoms or signs of tuberculosis during treatment, even if the initial testing is negative.
Satralizumab (applies to satralizumab) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Treatment with satralizumab can increase the risk of serious infections. Treatment should be delayed until any active infection is treated and resolved.
Switch to professional interaction data
Satralizumab drug interactions
There are 351 drug interactions with satralizumab.
Report options
More about satralizumab
- satralizumab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Uplizna
Uplizna is used to treat adults with neuromyelitis optic spectrum disorder (NMOSD) who are ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Soliris
Soliris infusion is used to treat adults with paroxysmal nocturnal hemoglobinuria (PNH), adults and ...
Enspryng
Enspryng is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Inebilizumab
Inebilizumab systemic is used for immunoglobulin g4-related disease, neuromyelitis optica spectrum ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
